Cyclic oligonucleotides as potential mucosal vaccine adjuvants

Cyclic oligonucleotides as potential mucosal vaccine adjuvants

Project No. 2047

Principal Investigator/Inventor: Dr. Hongbin (Tony) Yan, Department of Chemistry

A method for using cdiGMP and analogs as oral vaccine adjuvants to induce strong mucosal anti-bacterial immune responses.

The mucosal surfaces in humans (gastrointestinal, respiratory and urinary tracts) are the major portals of entry and/or sites of diseases caused by bacterial, viral or parasitic pathogens. The majority of current licensed human vaccines have only limited abilities to elicit a protective mucosal immunity. Dr. Yan and his collaborators have developed cyclic oligonucleotide analogues as adjuvants for the formulation of oral vaccines against bacterial infections. Vaccines formulated with antigens (such as protein antigens) and specific cyclic dinucleotide adjuvants (cdiGMP) can be administered orally to illicit immune responses that provide protective immunity against pathogen challenges by stimulating of the production of IgA antibodies from the mucosal system. In particular, this method has been demonstrated to protect mice from Helicobacter pylori infection, the major cause of gastric ulcers and a factor for increased risk of stomach cancer. Vaccines that elicit a strong and prolonged mucosal immunity represent a significant advancement in the prevention of a wide spectrum of infectious diseases.

Patent Status

Yan et al., “Use of fluorinated cyclic dinucleotides as oral vaccine adjuvants” US provisional patent application 61/710,254.

References

KuoLee, R., et al., (2010) cdiGMP as a mucosal vaccines adjuvant. Vaccine. 28: 3080.
Chen, W., et al., (2010) Recent advances in the development of novel mucosal adjuvants and antigen delivery systems. Human Vaccines. 6: 683.

 

Return to available to license